Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 7/20 | 0.46 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | F11 | P03951 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.39 |
| ▸ | MGLL | Q99685 | 2/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.38 |
| ▸ | USP14 | P54578 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | TTR | P02766 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9184213 | 0.84 | LPL (0.41) | LPLLIPGCA2CA1F11 | |
| SCHEMBL3653470 | 0.83 | LPL (0.49) | LPLLIPGCA2CA1F11 | |
| SCHEMBL906834 | 0.82 | IDO1 (0.48) | BACE1 | |
| SCHEMBL1241080 | 0.81 | ENPP2 (0.49) | LPLLIPGMGLLENPP2 | |
| SCHEMBL3178345 | 0.80 | PPARG (0.40) | USP14BACE1 | |
| SCHEMBL29952079 | 0.79 | BACE1 (0.36) | LPLLIPGCA2CA1ENPP2 | |
| SCHEMBL7358574 | 0.79 | LPL (0.39) | LPLLIPGCA2CA1F11 | |
| SCHEMBL12855670 | 0.78 | AGXT (0.52) | CA2CA1USP14 | |
| SCHEMBL15489965 | 0.78 | TDP1 (0.37) | LPLLIPGBACE1 | |
| SCHEMBL30401327 | 0.78 | IDO1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119677733-A | Bicyclic tetrahydrothiazepine derivatives | 豪夫迈·罗氏有限公司 | 2025-03-21 | — | — | CN | disclosed |
| US-20230234944-A1 | NOVEL COMPOUND USEFUL AS TOLL-LIKE RECEPTOR 7 ACTIVATION INHIBITOR | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2023-07-27 | — | — | US | disclosed |
| US-20230159491-A1 | Antimicrobial Compounds and Methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-25 | — | — | US | disclosed |
| EP-4166195-A1 | NOVEL COMPOUND USEFUL AS TOLL-LIKE RECEPTOR 7 ACTIVATION INHIBITOR | Toyama Prefectural University (JP) | 2023-04-19 | — | — | EP | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20220259226-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2022-08-18 | — | — | US | disclosed |
| EP-3911644-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | Curza Global LLC (US) | 2021-11-24 | — | — | EP | disclosed |
| US-20210292339-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2021-09-23 | — | — | US | disclosed |
| EP-3186245-B1 | MAPK INHIBITORS | EverBrilliant Pharma Pty Ltd (AU) | 2021-06-23 | — | — | EP | disclosed |
| CN-112739343-A | Macrocyclic MCL-1 inhibitors and methods of use | 艾伯维公司 | 2021-04-30 | — | — | CN | disclosed |
| US-20180289684-A1 | MAPK INHIBITORS | EverBrilliant Pharma Pty Ltd (AU) | 2018-10-11 | — | — | US | disclosed |
| US-20170266173-A1 | MAPK INHIBITORS | EVERBRILLIANT PHARMA PTY LTD. (AU) | 2017-09-21 | — | — | US | disclosed |
| EP-3186245-A1 | MAPK INHIBITORS | Wang, Bing Hui (AU) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016029263-A1 | MAPK INHIBITORS | WANG BING HUI (AU) | 2016-03-03 | — | — | WO | disclosed |
| US-5583130-A | Benzo-fused lactams promote release of growth hormone | MERCK & CO., INC. (US) | 1996-12-10 | — | — | US | disclosed |
| EP-0699196-A1 | CARBAZOLE DERIVATIVES WITH 17,20-LYASE-INHIBITING ACTIVITY | GLAXO GROUP LIMITED (GB) | 1996-03-06 | — | — | EP | disclosed |
| EP-0665748-A4 | BENZO-FUSED LACTAMS PROMOTE RELEASE OF GROWTH HORMONE. | — | 1995-08-23 | — | — | EP | disclosed |
| EP-0665748-A1 | BENZO-FUSED LACTAMS PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO. INC. (US) | 1995-08-09 | — | — | EP | disclosed |
| WO-1994027989-A1 | CARBAZOLE DERIVATIVES WITH 17,20-LYASE-INHIBITING ACTIVITY | GLAXO GROUP LIMITED (GB) | 1994-12-08 | — | — | WO | disclosed |
| WO-1994007486-A1 | BENZO-FUSED LACTAMS PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO., INC. (US) | 1994-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234944-A1 | NOVEL COMPOUND USEFUL AS TOLL-LIKE RECEPTOR 7 ACTIVATION INHIBITOR | TLR7, TLR6, TLR9 | LPL 1608/4885LIPG 2534/4885CA2 2350/4885 |
| US-20230159491-A1 | Antimicrobial Compounds and Methods | MPO, NISCH, RPN2 | LPL 3477/4885LIPG 3693/4885CA2 2151/4885 |
| US-20210292339-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | LPL 4441/4885LIPG 3835/4885CA2 4685/4885 |
| US-20170266173-A1 | MAPK INHIBITORS | MAPK1, MAPK4, MAPK3 | LPL 3302/4885LIPG 1961/4885CA2 4529/4885 |
| US-20220259226-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | LPL 4441/4885LIPG 3835/4885CA2 4685/4885 |
| US-20180289684-A1 | MAPK INHIBITORS | MAPK1, MAPK4, MAPK3 | LPL 3302/4885LIPG 1961/4885CA2 4529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.